Berhampur: As the days are progressing, our understanding for type 2 Diabetes is increasing and scientists have been working to invent new molecules to address newer aspects of Type 2 Diabetes. SEMAGLUTIDE is a novel oral drug approved for treatment of Type 2 Diabetes across 6 countries of globe including India. It acts on Pancreas to increase Insulin, reduce Glucagon (A hormone increasing blood sugar), enhances glucose entry into muscles, reduces liver glucose production, reduces appetite acting on brain and stomach. There are 8 PIONEER studies on this drug which have demonstrated significant blood glucose reduction along with weight loss, very low risk of hypoglycemia along with protection to heart and kidney. This has one additional property of increasing the number of insulin producing beta cells in the pancreas.
A launching session for this drug for South Odisha was conducted under the banner of Endocrine Society of Odisha under the chairmanship of Dr Sunil Kota, Endocrinologist at Diabetes & Endocare Clinic, Berhampur. Dr Kota highlighted its invention and different clinical trials. This class of drugs were there earlier in firm of injection. This is the first such Oral drug and a first protein drug in a tablet form. There were 5 different sessions and panel discussions delivered by physicians, cardiologist, nephrolosist and neurologist. Dr Trinath Mishra from Cardiology, Dr Amalendu Jena from Nephrology, Prof P C Sahu and other physicians like Dr J Bharatudu, Dr Amar Das, Dr Satya Sethy, Dr P M R Subudhi, Dr Satya Sethy, Dr E Venkata Krishna were among the faculties. Total of around 80 doctors in and around from different places of South Odisha attended the meet. Lastly Dr Sunil Kota summarized about the molecule and extended vote of thanks
